Compare Stocks: CTOR, IVVD, ACIU, and MGNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.91 +1.7%	$2.43	$2.03 ▼ $4.00	$296.15M	1.59	289,150 shs	112,290 shs
CTOR Citius Oncology	$0.79 +5.9%	$0.68	$0.49 ▼ $2.25	$72.99M	3.48	167,910 shs	103,617 shs
IVVD Invivyd	$0.93 -0.9%	$0.78	$0.53 ▼ $3.07	$275.31M	0.71	3.60 million shs	1.20 million shs
MGNX MacroGenics	$4.15 +3.1%	$4.24	$1.29 ▼ $5.08	$263.40M	1.2	1.03 million shs	112,581 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-1.38%	+13.04%	+28.25%	-2.39%	+33.02%
CTOR Citius Oncology	+0.83%	+1.35%	+33.40%	-12.79%	-57.14%
IVVD Invivyd	-5.42%	+27.28%	+54.15%	-14.32%	+81.22%
MGNX MacroGenics	-1.95%	-0.99%	+8.65%	-10.07%	+137.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.91 +1.7%	$2.43	$2.03 ▼ $4.00	$296.15M	1.59	289,150 shs	112,290 shs
CTOR Citius Oncology	$0.79 +5.9%	$0.68	$0.49 ▼ $2.25	$72.99M	3.48	167,910 shs	103,617 shs
IVVD Invivyd	$0.93 -0.9%	$0.78	$0.53 ▼ $3.07	$275.31M	0.71	3.60 million shs	1.20 million shs
MGNX MacroGenics	$4.15 +3.1%	$4.24	$1.29 ▼ $5.08	$263.40M	1.2	1.03 million shs	112,581 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-1.38%	+13.04%	+28.25%	-2.39%	+33.02%
CTOR Citius Oncology	+0.83%	+1.35%	+33.40%	-12.79%	-57.14%
IVVD Invivyd	-5.42%	+27.28%	+54.15%	-14.32%	+81.22%
MGNX MacroGenics	-1.95%	-0.99%	+8.65%	-10.07%	+137.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.40	Hold	$7.50	157.73% Upside
CTOR Citius Oncology	2.33	Hold	$6.00	655.67% Upside
IVVD Invivyd	2.33	Hold	$8.00	756.53% Upside
MGNX MacroGenics	2.17	Hold	$6.33	52.79% Upside

Current Analyst Ratings Breakdown

Latest CTOR, IVVD, ACIU, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/5/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$4.31M	68.71	N/A	N/A	$0.54 per share	5.39
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.54 per share	N/A
IVVD Invivyd	$58.37M	4.72	N/A	N/A	$1.04 per share	0.90
MGNX MacroGenics	$175.14M	1.51	N/A	N/A	$0.88 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.54	N/A	17.12	N/A	-245.32%	-100.17%	-28.36%	11/3/2026 (Estimated)
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest CTOR, IVVD, ACIU, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/6/2026	Q2 2026	ACIU AC Immune	-$0.1044	$0.03	+$0.1344	$0.03	$9.59 million	$18.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.93	1.02
CTOR Citius Oncology	0.25	0.73	0.34
IVVD Invivyd	N/A	5.87	5.87
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CTOR Citius Oncology	70.52%
IVVD Invivyd	70.36%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CTOR Citius Oncology	9.80%
IVVD Invivyd	12.25%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.87 million	N/A
IVVD Invivyd	100	294.76 million	258.65 million	Optionable
MGNX MacroGenics	430	63.70 million	55.04 million	Optionable

CTOR, IVVD, ACIU, and MGNX Headlines

Recent News About These Companies

MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

August 21, 2026 | insidertrades.com

Insider Selling: MacroGenics (NASDAQ:MGNX) VP Sells 31,105 Shares of Stock

August 20, 2026 | marketbeat.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

August 20, 2026 | zacks.com

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

August 13, 2026 | marketbeat.com

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

August 13, 2026 | globenewswire.com

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP

August 13, 2026 | marketbeat.com

MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 12, 2026 | finanznachrichten.de

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 11, 2026 | globenewswire.com

MacroGenics (MGNX) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages

August 3, 2026 | marketbeat.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

MacroGenics slips after early-stage trial data for lead asset

July 24, 2026 | seekingalpha.com

MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 24, 2026 | finanznachrichten.de

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 23, 2026 | tmcnet.com

MacroGenics announces upcoming board change with director resignation

July 8, 2026 | tipranks.com

Bora Pharmaceuticals closes 122 million buy of MacroGenics Rockville manufacturing site

July 4, 2026 | msn.com

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

July 2, 2026 | usatoday.com

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

July 2, 2026 | zacks.com

MacroGenics Completes Sale of GMP Drug Substance Manufacturing Operations to Bora Pharmaceuticals

July 2, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTOR, IVVD, ACIU, and MGNX Company Descriptions

AC Immune NASDAQ:ACIU

$2.91 +0.05 (+1.75%)

As of 01:25 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Citius Oncology NASDAQ:CTOR

$0.79 +0.04 (+5.87%)

As of 01:27 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Invivyd NASDAQ:IVVD

$0.93 -0.01 (-0.90%)

As of 01:28 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

MacroGenics NASDAQ:MGNX

$4.14 +0.13 (+3.11%)

As of 01:27 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, IVVD, ACIU, and MGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, IVVD, ACIU, and MGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, IVVD, ACIU, and MGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, IVVD, ACIU, and MGNX Company Descriptions

AC Immune NASDAQ:ACIU

Citius Oncology NASDAQ:CTOR

Invivyd NASDAQ:IVVD

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, IVVD, ACIU, and MGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, IVVD, ACIU, and MGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, IVVD, ACIU, and MGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, IVVD, ACIU, and MGNX Company Descriptions

AC Immune NASDAQ:ACIU

Citius Oncology NASDAQ:CTOR

Invivyd NASDAQ:IVVD

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools